Pacific Biosciences Of California Stock News

The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.

Pacific Biosciences of California Inc (PACB) shares closed today 11.1% higher than it did at the end of yesterday. The stock is currently down 50.8% year-to-date, down 68.9% over the past 12 months, and up 110.5% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $11.26 and as low as $9.08 this week.Shares closed 79.2% below its 52-week high and 23.7% above its 52-week low.Trading volume this week was 23.4% higher than the 10-day average and 41.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 248.3% The company's stock price performance over the past 12 months lags the peer average by 354.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

Could these biotech stocks be poised for gains in 2022?

MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee

Companies in The News Are: ACCD,PACB,BIG,ILMN

Pacific Biosciences of California Inc (PACB) shares closed this week 20.7% lower than it did at the end of last week. The stock is currently down 19.0% year-to-date, down 54.8% over the past 12 months, and up 230.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $21.01 and as low as $15.58 this week.Trading volume this week was 10.6% higher than the 10-day average and 38.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 154.1% The company's stock price performance over the past 12 months lags the peer average by 556.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Preliminary fourth-quarter results reached a record high but didn't quite meet expectations.